GH and Childhood-onset Craniopharyngioma: When to Initiate GH Replacement Therapy?
The Journal of Clinical Endocrinology & Metabolism · 2023
DOI: 10.1210/clinem/dgad079 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2023. Verfasst von Adrien Nguyen Quoc und 25 weiteren Autor:innen. Beteiligte Einrichtung: Paediatric Endocrinology, Diabetology, Gynaecology Department, Necker-Enfants Malades University Hospital, AP-HP Centre, 75015 Paris, France. Hauptthemen laut MEDLINE: Craniopharyngioma, Pituitary Neoplasms, Human Growth Hormone. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 45 Literaturangaben.
Abstract (Originalsprache)
Context
Craniopharyngioma is a benign brain tumor with frequent local recurrence or progression after treatment. GH replacement therapy (GHRT) is prescribed in children with GH deficiency resulting from childhood-onset craniopharyngioma.
Objective
To evaluate whether a shorter delay of GHRT initiation after childhood-onset craniopharyngioma completion therapy increased the risk of a new event (progression or recurrence).
Methods
Retrospective, observational, monocenter study. We compared a cohort of 71 childhood-onset patients with craniopharyngiomas treated with recombinant human GH (rhGH). Twenty-seven patients were treated with rhGH at least 12 months after craniopharyngioma treatment (>12-month group) and 44 patients before 12 months (<12-month group), among which 29 patients were treated between 6 and 12 months (6-12 month group). The main outcome was the risk of tumor new event (progression of residual tumor or tumor recurrence after complete resection) after primary treatment in the >12-month group and in the <12 month or in the 6- to 12-month group patients.
Results
In the >12-month group, the 2- and 5-year event-free survivals were respectively 81.5% (95% CI, 61.1-91.9) and 69.4% (95% CI, 47.9-83.4) compared with 72.2% (95% CI, 56.3-83.1) and 69.8% (95% CI, 53.8-81.2) in the <12-month group. The 2- and 5-year event-free survivals were the same in the 6- to 12-month group (72.4%; 95% CI, 52.4-85.1). By log-rank test, the event-free survival was not different between groups (P = .98 and P = .91). The median time for event was not statistically different. In univariate and multivariate analysis, the risk of craniopharyngioma new event was not associated with the GHRT time delay after craniopharyngioma treatment.
Conclusions
No association was found between GHRT time delay after childhood-onset craniopharyngioma treatment and an increased risk of recurrence or tumor progression, suggesting GH replacement therapy can be initiated 6 months after last treatment for craniopharyngiomas.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Paediatric Endocrinology, Diabetology, Gynaecology Department, Necker-Enfants Malades University Hospital, AP-HP Centre, 75015 Paris, France.
- Faculty of medicine, Université Paris Cité, 75006 Paris, France.
- Department of Pediatric Neurosurgery, Necker-Enfants Malades University Hospital, AP-HP Centre, 75015 Paris, France.
- Cochin Institute, INSERM U1016, 75014 Paris, France.
- IMAGINE Institute Affiliate, INSERM U1163, 75015 Paris, France.
- Radiation Oncology Department, Curie Institute, 75005 Paris, France.
ORCID-Profile: Adrien Nguyen Quoc
Zitieren
APA
Nguyen Quoc, A., Beccaria, K., González Briceño, L., Pinto, G., Samara-Boustani, D., Stoupa, A., Beltrand, J., Besançon, A., Thalassinos, C., Puget, S., Blauwblomme, T., Alapetite, C., Bolle, S., Doz, F., Grill, J., Dufour, C., Bourdeaut, F., Abbou, S., Guerrini-Rousseau, L., …, & Kariyawasam, D. (2023). GH and Childhood-onset Craniopharyngioma: When to Initiate GH Replacement Therapy?. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad079
Vancouver
Nguyen Quoc A, Beccaria K, González Briceño L, Pinto G, Samara-Boustani D, Stoupa A, et al. GH and Childhood-onset Craniopharyngioma: When to Initiate GH Replacement Therapy?. The Journal of Clinical Endocrinology & Metabolism. 2023. doi:10.1210/clinem/dgad079
BibTeX
@article{NguyenQuoc2023,
author = {Nguyen Quoc, Adrien and Beccaria, Kévin and González Briceño, Laura and Pinto, Graziella and Samara-Boustani, Dinane and Stoupa, Athanasia and Beltrand, Jacques and Besançon, Alix and Thalassinos, Caroline and Puget, Stéphanie and Blauwblomme, Thomas and Alapetite, Claire and Bolle, Stéphanie and Doz, François and Grill, Jacques and Dufour, Christelle and Bourdeaut, Franck and Abbou, Samuel and Guerrini-Rousseau, Léa and Leruste, Amaury and Brabant, Séverine and Cavadias, Iphigénie and Viaud, Magali and Boddaert, Nathalie and Polak, Michel and Kariyawasam, Dulanjalee},
title = {GH and Childhood-onset Craniopharyngioma: When to Initiate GH Replacement Therapy?},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2023},
doi = {10.1210/clinem/dgad079}
}
EUVIMED